ATE163927T1 - 1,4-benzothiazepine verwendbar als neurologische mittel - Google Patents

1,4-benzothiazepine verwendbar als neurologische mittel

Info

Publication number
ATE163927T1
ATE163927T1 AT94900113T AT94900113T ATE163927T1 AT E163927 T1 ATE163927 T1 AT E163927T1 AT 94900113 T AT94900113 T AT 94900113T AT 94900113 T AT94900113 T AT 94900113T AT E163927 T1 ATE163927 T1 AT E163927T1
Authority
AT
Austria
Prior art keywords
alkyl
optionally substituted
halo
phenyl
alkoxy
Prior art date
Application number
AT94900113T
Other languages
English (en)
Inventor
John Rosindale Housley
James Edward Jeffery
Kenneth John Nichol
Bruce Jeremy Sargent
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929223443A external-priority patent/GB9223443D0/en
Priority claimed from GB929223441A external-priority patent/GB9223441D0/en
Application filed by Knoll Ag filed Critical Knoll Ag
Application granted granted Critical
Publication of ATE163927T1 publication Critical patent/ATE163927T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94900113T 1992-11-09 1993-11-06 1,4-benzothiazepine verwendbar als neurologische mittel ATE163927T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929223443A GB9223443D0 (en) 1992-11-09 1992-11-09 Therapeutic agents
GB929223441A GB9223441D0 (en) 1992-11-09 1992-11-09 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE163927T1 true ATE163927T1 (de) 1998-03-15

Family

ID=26301938

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94900113T ATE163927T1 (de) 1992-11-09 1993-11-06 1,4-benzothiazepine verwendbar als neurologische mittel

Country Status (22)

Country Link
US (1) US5580866A (de)
EP (1) EP0667866B1 (de)
JP (1) JPH08503202A (de)
KR (1) KR100313649B1 (de)
AT (1) ATE163927T1 (de)
BG (1) BG62519B1 (de)
BR (1) BR9307387A (de)
CA (1) CA2148584A1 (de)
CZ (1) CZ288595B6 (de)
DE (1) DE69317436T2 (de)
DK (1) DK0667866T3 (de)
ES (1) ES2113081T3 (de)
FI (1) FI952204A0 (de)
GR (1) GR3026386T3 (de)
HU (1) HUT71819A (de)
NO (1) NO304467B1 (de)
NZ (1) NZ257843A (de)
PL (1) PL179401B1 (de)
RU (1) RU2115650C1 (de)
SK (1) SK280522B6 (de)
UA (1) UA41342C2 (de)
WO (1) WO1994011360A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ES2190428T3 (es) * 1991-06-28 2003-08-01 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogeno.
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US6458784B1 (en) 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
ZA9610853B (en) 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.
GB9616279D0 (en) * 1996-08-02 1996-09-11 Knoll Ag Chemical process
PT864582E (pt) * 1997-03-14 2003-10-31 Aventis Pharma Gmbh 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos
GB9914745D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1603450A4 (de) 2003-03-07 2009-07-29 Univ Columbia Verfahren auf basis von typ 1 ryanodin-rezeptor
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
RS52172B (en) 2008-03-03 2012-08-31 Les Laboratoires Servier PROCEDURE FOR THE PRODUCTION OF BENZOTHIAZEPINE FROM GAMA-AMINOALKYLBENZENE
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
EP2708535A1 (de) * 2012-05-11 2014-03-19 Les Laboratoires Servier Mittel zur Behandlung von Erkrankungen durch Modulation von Ryanodin-Rezeptoren
KR102157141B1 (ko) 2018-11-27 2020-09-17 주식회사 파미니티 으아리 추출물을 유효 성분으로 포함하는 인지 기능 개선용 조성물
KR102172916B1 (ko) 2018-12-07 2020-11-02 주식회사 파미니티 실크 펩타이드 및 천연 추출물을 포함하는 인지 기능 개선용 조성물
KR20230129394A (ko) * 2020-11-17 2023-09-08 암고 파마, 인크. 리아노딘 수용체를 수반하는 장애를 치료하기 위한 작용제
AU2022205964A1 (en) 2021-01-08 2023-08-17 Armgo Pharma, Inc. Crystalline forms of a ryanodine receptor modulator and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362962A (en) * 1964-01-24 1968-01-09 Hoffmann La Roche Certain benzothiazepine derivatives
US3682962A (en) * 1970-03-17 1972-08-08 Sterling Drug Inc 1-substituted-1,2,3,5-tetrahydro-4,1-benzothiozepines
DE58901634D1 (de) * 1988-11-05 1992-07-16 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen.
JP2703408B2 (ja) * 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
GB9111376D0 (en) * 1991-05-25 1991-07-17 Boots Co Plc Therapeutic agents
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds

Also Published As

Publication number Publication date
EP0667866A1 (de) 1995-08-23
BG62519B1 (bg) 2000-01-31
HUT71819A (en) 1996-02-28
PL308757A1 (en) 1995-08-21
NO304467B1 (no) 1998-12-21
NO951797D0 (no) 1995-05-08
DE69317436T2 (de) 1998-07-02
GR3026386T3 (en) 1998-06-30
DK0667866T3 (da) 1998-05-25
CA2148584A1 (en) 1994-05-26
UA41342C2 (uk) 2001-09-17
NO951797L (no) 1995-05-24
PL179401B1 (pl) 2000-08-31
FI952204A (fi) 1995-05-08
BR9307387A (pt) 1999-08-31
NZ257843A (en) 1996-10-28
FI952204A0 (fi) 1995-05-08
AU5464494A (en) 1994-06-08
RU2115650C1 (ru) 1998-07-20
BG99679A (bg) 1996-04-30
ES2113081T3 (es) 1998-04-16
SK280522B6 (sk) 2000-03-13
KR100313649B1 (ko) 2002-02-28
HU9501352D0 (en) 1995-06-28
WO1994011360A1 (en) 1994-05-26
JPH08503202A (ja) 1996-04-09
RU95112484A (ru) 1997-04-20
EP0667866B1 (de) 1998-03-11
SK58895A3 (en) 1995-09-13
CZ288595B6 (cs) 2001-07-11
CZ117695A3 (en) 1996-06-12
AU680639B2 (en) 1997-08-07
KR950704283A (ko) 1995-11-17
DE69317436D1 (de) 1998-04-16
US5580866A (en) 1996-12-03

Similar Documents

Publication Publication Date Title
ATE163927T1 (de) 1,4-benzothiazepine verwendbar als neurologische mittel
PL323666A1 (en) Semicarbasones acting on central nervous system and pharmaceutic agents containing them
ATE225205T1 (de) Dispergiermittel
ATE168991T1 (de) Substituierte arylalkoxybenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
ZA943241B (en) Therapeutic agents
ATE152442T1 (de) Substituierte arylalkylaminobenzyl- aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
IL107486A0 (en) Therapeutic agents
JO1621B1 (en) Therapeutic agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee